Cargando…

The effect of umeclidinium added to inhaled corticosteroid/long-acting β(2)-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study

Benefits of triple therapy with a long-acting muscarinic antagonist (LAMA), added to inhaled corticosteroid (ICS)/long-acting β(2)-agonist (LABA), have been demonstrated. Limited data assessing the efficacy of the LAMA umeclidinium (UMEC) added to ICS/LABA are available. The aim of this study is to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sousa, Ana R, Riley, John H, Church, Alison, Zhu, Chang-Qing, Punekar, Yogesh S, Fahy, William A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918053/ https://www.ncbi.nlm.nih.gov/pubmed/27334739 http://dx.doi.org/10.1038/npjpcrm.2016.31

Ejemplares similares

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
por: Kerwin, Edward M, et al.
Publicado: (2017)

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
por: Rheault, Tara, et al.
Publicado: (2016)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
por: Singh, Dave, et al.
Publicado: (2016)

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD
por: Siler, Thomas M, et al.
Publicado: (2016)

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies
por: Siler, Thomas M., et al.
Publicado: (2016)

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK
por: Punekar, Yogesh Suresh, et al.
Publicado: (2015)

Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol
por: Albertson, Timothy E, et al.
Publicado: (2015)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
por: Albertson, Timothy E, et al.
Publicado: (2019)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD
por: Feldman, Gregory, et al.
Publicado: (2016)

A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
por: Kerwin, Edward, et al.
Publicado: (2020)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study
por: Zheng, Jinping, et al.
Publicado: (2015)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
por: Shukla, Soham, et al.
Publicado: (2021)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
por: Molino, Antonio, et al.
Publicado: (2018)

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
por: Miravitlles, Marc, et al.
Publicado: (2016)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
por: Huang, Tsan-Ming, et al.
Publicado: (2020)

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study
por: Riley, John H., et al.
Publicado: (2018)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
por: Mehta, Rashmi, et al.
Publicado: (2018)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
por: Oba, Yuji, et al.
Publicado: (2014)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
por: Rottenkolber, Marietta, et al.
Publicado: (2015)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β(2)-agonist via dry-powder inhalers and pressurized metered-dose inhalers
por: Wittbrodt, Eric T, et al.
Publicado: (2018)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
por: Alakeel, Yousif S., et al.
Publicado: (2022)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Inhaled corticosteroids in COPD: Personalising the therapeutic choice
por: Shaw, J A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l50icp4eb077k8o0omjsclijme